South Korea · Delayed Price · Currency is KRW JW Lifescience Statistics
Total Valuation
JW Lifescience has a market cap or net worth of KRW 170.33 billion. The enterprise value is 190.62 billion.
| Market Cap | 170.33B |
| Enterprise Value | 190.62B |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | Mar 31, 2026 |
Share Statistics
JW Lifescience has 15.48 million shares outstanding. The number of shares has increased by 0.01% in one year.
| Current Share Class | 15.48M |
| Shares Outstanding | 15.48M |
| Shares Change (YoY) | +0.01% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.11% |
| Owned by Institutions (%) | 11.21% |
| Float | 8.56M |
Valuation Ratios
The trailing PE ratio is 6.55.
| PE Ratio | 6.55 |
| Forward PE | n/a |
| PS Ratio | 0.67 |
| PB Ratio | 0.75 |
| P/TBV Ratio | 1.13 |
| P/FCF Ratio | 4.79 |
| P/OCF Ratio | 3.55 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 3.68, with an EV/FCF ratio of 5.36.
| EV / Earnings | 7.33 |
| EV / Sales | 0.75 |
| EV / EBITDA | 3.68 |
| EV / EBIT | 5.72 |
| EV / FCF | 5.36 |
Financial Position
The company has a current ratio of 1.25, with a Debt / Equity ratio of 0.14.
| Current Ratio | 1.25 |
| Quick Ratio | 0.80 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | 0.62 |
| Debt / FCF | 0.91 |
| Interest Coverage | 11.75 |
Financial Efficiency
Return on equity (ROE) is 11.92% and return on invested capital (ROIC) is 10.93%.
| Return on Equity (ROE) | 11.92% |
| Return on Assets (ROA) | 6.74% |
| Return on Invested Capital (ROIC) | 10.93% |
| Return on Capital Employed (ROCE) | 13.87% |
| Weighted Average Cost of Capital (WACC) | 5.80% |
| Revenue Per Employee | 854.23M |
| Profits Per Employee | 87.61M |
| Employee Count | 297 |
| Asset Turnover | 0.82 |
| Inventory Turnover | 5.71 |
Taxes
In the past 12 months, JW Lifescience has paid 5.97 billion in taxes.
| Income Tax | 5.97B |
| Effective Tax Rate | 18.66% |
Stock Price Statistics
The stock price has decreased by -8.18% in the last 52 weeks. The beta is 0.24, so JW Lifescience's price volatility has been lower than the market average.
| Beta (5Y) | 0.24 |
| 52-Week Price Change | -8.18% |
| 50-Day Moving Average | 11,253.60 |
| 200-Day Moving Average | 12,436.70 |
| Relative Strength Index (RSI) | 41.45 |
| Average Volume (20 Days) | 15,651 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, JW Lifescience had revenue of KRW 253.71 billion and earned 26.02 billion in profits. Earnings per share was 1,680.36.
| Revenue | 253.71B |
| Gross Profit | 71.58B |
| Operating Income | 33.33B |
| Pretax Income | 31.99B |
| Net Income | 26.02B |
| EBITDA | 51.81B |
| EBIT | 33.33B |
| Earnings Per Share (EPS) | 1,680.36 |
Balance Sheet
The company has 12.08 billion in cash and 32.37 billion in debt, with a net cash position of -20.29 billion or -1,310.11 per share.
| Cash & Cash Equivalents | 12.08B |
| Total Debt | 32.37B |
| Net Cash | -20.29B |
| Net Cash Per Share | -1,310.11 |
| Equity (Book Value) | 226.76B |
| Book Value Per Share | 14,644.44 |
| Working Capital | 16.53B |
Cash Flow
In the last 12 months, operating cash flow was 47.97 billion and capital expenditures -12.39 billion, giving a free cash flow of 35.59 billion.
| Operating Cash Flow | 47.97B |
| Capital Expenditures | -12.39B |
| Depreciation & Amortization | 18.48B |
| Net Borrowing | -25.67B |
| Free Cash Flow | 35.59B |
| FCF Per Share | 2,298.12 |
Margins
Gross margin is 28.21%, with operating and profit margins of 13.14% and 10.26%.
| Gross Margin | 28.21% |
| Operating Margin | 13.14% |
| Pretax Margin | 12.61% |
| Profit Margin | 10.26% |
| EBITDA Margin | 20.42% |
| EBIT Margin | 13.14% |
| FCF Margin | 14.03% |
Dividends & Yields
This stock pays an annual dividend of 500.00, which amounts to a dividend yield of 4.46%.
| Dividend Per Share | 500.00 |
| Dividend Yield | 4.46% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 32.73% |
| Buyback Yield | -0.01% |
| Shareholder Yield | 4.46% |
| Earnings Yield | 15.28% |
| FCF Yield | 20.89% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on April 20, 2018. It was a forward split with a ratio of 2.
| Last Split Date | Apr 20, 2018 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
JW Lifescience has an Altman Z-Score of 3.48 and a Piotroski F-Score of 6.
| Altman Z-Score | 3.48 |
| Piotroski F-Score | 6 |